Skip to Content
Merck
CN
  • Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate using an iodolactamization as the key step.

Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate using an iodolactamization as the key step.

The Journal of organic chemistry (2009-07-11)
Carlton L Campbell, Carla Hassler, Soo S Ko, Matthew E Voss, Michael A Guaciaro, Percy H Carter, Robert J Cherney
ABSTRACT

An efficient enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate 2, an essential intermediate for a series of potent CCR2 antagonists, is described. The key step in the sequence is an iodolactamization to yield the highly functionalized (1R,2S,4S,5S)-tert-butyl 2-(benzyloxycarbonylamino)-4-iodo-7-oxo-6-azabicyclo[3.2.1]octane-6-carboxylate 11. An examination of the reaction mechanism within the 2-step iodolactamization sequence led to the discovery of a single-pot transformation of increased efficiency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phthalic anhydride, ReagentPlus®, 99%
Sigma-Aldrich
Phthalic anhydride, ACS reagent, ≥99%